Deep Medicine IDEA Pharma

Childhood trauma and the development of adult affective disorders: correlation or causation?

Unraveling the role of amyloid in cardiomyopathy

Welcome to this, the second in the series of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Today Alex has been joined by Mark Emberton, Dean, Faculty of Medical Sciences, University College London, Professor of Interventional Oncology, Division of Surgery and Interventional Science, UCL, and an Honorary Consultant Urologist at University College London Hospitals NHS Trust. Mark has been at the forefront of imaging techniques for early prostate cancer detection, changing the detection paradigm in UK (and beyond) through his pioneering work with MRI. He has also driven the practice of minimally-invasive treatment techniques such as HIFU for early prostate cancer treatment. Alex had a chance to discuss state-of-the-art in early detection with Mark, and consider where future data might lead us in better detecting, categorizing, and managing early prostate cancer.

Welcome to this, the first in the series of Deep Medicine, with your host Dr Alexander Gray, the Chief Medical Officer of IDEA Pharma. Today Alex has been joined by Alexander Leff, Professor of Cognitive Neurology and Consultant Neurologist, Department of Brain Repair and Rehabilitation, at the Institute of Neurology, University College London, London, UK. Professor Leff is a pioneer in the field of cognitive rehabilitation. Alex had a chance to discuss with him the differences he sees between cognitive deficits in psychiatric conditions versus those in people who have had a stroke, and discuss the boundaries between behavioural approaches and potential pharmacologic strategies in managing patients with different types of cognitive impairment.